These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1115054)

  • 21. Association between plasma high density lipoprotein cholesterol and antipyrine metabolism in alcoholics.
    Cushman P; Barboriak JJ; Liao A; Hoffman NE
    Life Sci; 1982 May; 30(20):1721-4. PubMed ID: 7098769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antipyrine elimination and hepatic microsomal enzyme activity in patients with liver disease.
    Wensing G; Ohnhaus EE; Hoensch HP
    Clin Pharmacol Ther; 1990 Jun; 47(6):698-705. PubMed ID: 2113450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipyrine pharmacokinetics and D-glucaric excretion in kwashiorkor.
    Buchanan N; Eyberg C; Davis MD
    Am J Clin Nutr; 1979 Dec; 32(12):2439-42. PubMed ID: 506967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum LDL cholesterol, the LDL/HDL cholesterol ratio and liver microsomal enzyme induction evaluated by antipyrine kinetics.
    Luoma PV; Sotaniemi EA; Arranto AJ
    Scand J Clin Lab Invest; 1983 Dec; 43(8):671-5. PubMed ID: 6665516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of microsomal enzyme activity by flupenthixol in chronic schizophrenics.
    Salem SA; King DJ; McDevitt DG
    Psychopharmacology (Berl); 1982; 78(2):147-9. PubMed ID: 6817372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antipyrine clearance in pneumonia.
    Sonne J; Døssing M; Loft S; Andreasen PB
    Clin Pharmacol Ther; 1985 Jun; 37(6):701-4. PubMed ID: 4006370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipyrine clearance and metabolism in patients with psoriasis.
    Kubota K; Ishizaki T; Chiba K; Takagi A; Nakagawa A; Nakamura K
    Br J Clin Pharmacol; 1986 Oct; 22(4):455-62. PubMed ID: 3768257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic microsomal drug metabolism, glutamyl transferase activity and in vivo antipyrine half-life in rats chronically fed an ethanol diet, a control diet and a chow diet.
    Gadeholt G; Aarbakke J; Dybing E; Sjöblom M; Mørland J
    J Pharmacol Exp Ther; 1980 Apr; 213(1):196-203. PubMed ID: 6102148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biliary lipid secretion in cholesterol gallstone disease. The effect of cholecystectomy and obesity.
    Shaffer EA; Small DM
    J Clin Invest; 1977 May; 59(5):828-40. PubMed ID: 856870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of whole-body irradiation on the half-life of antipyrine and on the microsomal enzyme system of rats. Correlation between in vivo and in vitro results.
    Thiriot C; Gaboriaud F; Bernard P
    Enzyme; 1983; 30(3):205-8. PubMed ID: 6354704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Irreversible binding of 3-14C-antipyrine to hepatic protein in vivo and in metabolizing liver microsomes.
    Tabarelli-Poplawski S; Uehleke H
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Mar; 297(1):105-10. PubMed ID: 859644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic metabolic ability during anaesthesia. Evaluation of antipyrine half-lives and their relation to enflurane metabolism.
    Oikkonen M; Rosenberg PH; Neuvonen PJ
    Anaesthesia; 1984 Jul; 39(7):660-5. PubMed ID: 6465491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enflurane anesthesia and antipyrine metabolism.
    Duvaldestin P; Mauge F; Desmonts JM
    Clin Pharmacol Ther; 1981 Jan; 29(1):61-4. PubMed ID: 7460476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antipyrine metabolism and liver function in patients treated with high-dose medroxyprogesterone.
    Rautio A; Kauppila AJ; Tuimala RJ; Sotaniemi EA
    Biomedicine; 1979 Sep; 31(5):135-8. PubMed ID: 508896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
    Branch RA; James JA; Read AE
    Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetic differences in the inhibitory effect of cimetidine on the metabolism of antipyrine.
    Gachályi B; Vas A; Csillag K; Nagy B; Kocsis F; Káldor A
    Eur J Clin Pharmacol; 1987; 31(5):613-5. PubMed ID: 3830247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antipyrine metabolism in patients with diabetes mellitus.
    Murali KV; Adithan C; Shashindran CH; Gambhir SS; Chandrasekar S
    Clin Exp Pharmacol Physiol; 1983; 10(1):7-13. PubMed ID: 6839551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
    Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
    Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of hepatic drug metabolism by glutethimide in patients with liver disease.
    Farrell GC; Cooksley WG; Powell LW
    Eur J Clin Pharmacol; 1979 Sep; 16(2):113-7. PubMed ID: 499307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesterol crystals and the formation of cholesterol gallstones.
    Sedaghat A; Grundy SM
    N Engl J Med; 1980 Jun; 302(23):1274-7. PubMed ID: 7366692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.